Close

Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On Dashboard Aug 11, 2021 08:30AM
Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD) Aug 4, 2021 08:30AM
FMW Media, Inc.’s New to The Street TV Announces its 5 TV Interviews Being Broadcasted On Fox Business Network, Tonight, Monday, August 2, 2021 @ 10:30 PM PT and Tomorrow, Tuesday, August 3, 2021 @ Aug 2, 2021 01:25PM
Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave Jul 29, 2021 08:30AM
New To The Street / Newsmax TV Announces 7 Interviews for This Weeks’ TV Broadcast, Sunday, July 25, 2021, Hour Slot 10-11 AM ET Jul 23, 2021 10:31AM


Jul 13, 2021 08:30AM Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities
Jul 9, 2021 09:30AM Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami
Jun 15, 2021 09:31AM Dr. Jeffrey Kamlet Internationally Recognized Expert on Cardiac Safety in Ibogaine Treatment Joins Ehave as Chief Medical Officer
May 20, 2021 06:30AM Ehave KetaDASH Subsidiary Commences Data Collection for Potential Patients and Partnering Clinics
Apr 22, 2021 12:32PM Ehave, Inc. Announces Engagement of Legal Counsel to Advise on Launch of KetaDASH in Miami Metro Area and across United States; Ehave Creates Path to Revenue Stream
Apr 16, 2021 07:30AM Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology
Mar 12, 2021 12:01PM Ehave CEO Benjamin Kaplan to be Featured on Psychedelic Spotlight Segment of New to the Street Airing on NewsMax on Sunday March 14th at 10:00 AM EST and Fox Business March 15th at 7:30 PM EST
Mar 3, 2021 08:30AM Ehave Inc. Files for KetaDash Trademark and to Uplist its Shares to the OTCQB
Feb 26, 2021 11:38AM Ehave Inc. Reaches Milestone; Ketamine IV Therapy Provider KetaDASH to Launch Beta in Second Quarter 2021
Feb 17, 2021 08:30AM Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithm
Feb 1, 2021 08:30AM Ehave Couples KetaDASH with Digital Therapeutics Expertise to Combat Clinical Depression
Jan 27, 2021 08:30AM Ehave Looks to Expand KetaDASH to Palliative Care
Jan 25, 2021 08:30AM Ehave, Inc. Utilizes Artificial Intelligence and Machine Learning for Big Data Management in Mental Healthcare
Jan 22, 2021 08:30AM Ehave Closes Transaction to Acquire CureDash Assets, Adds KetaDASH Home Delivery Service for Ketamine Clinics
Jan 21, 2021 08:51AM Ehave Revolutionizes Patient Medical Records for Psychedelic Mental Health
Jan 20, 2021 08:30AM Ehave, Inc. Closes 20/20 Global Transaction, Mycotopia Therapy Now Operating as a Publicly Traded Company with Intent to Focus on Psychedelic Sector
Jan 11, 2021 08:30AM Ehave Forms Partnership with Cognitive Apps to Introduce Revolutionary AI Voice Assistant That Will Revolutionize Mental Health in Psychedelic Sector
Jan 8, 2021 08:30AM Ehave, Inc. names Patrick Gallagher Director of Sales and Customer Acquisition
Jan 7, 2021 08:30AM Ehave, Inc. Partners with Cognitive Apps to Add Artificial Intelligence-Powered Mental Health Analytical Platform for Psychedelic Use in G20 Countries
Jan 4, 2021 08:30AM Ehave, Inc. Files to List on the Canadian Stock Exchange and Applies to Upgrade to OTCQB Exchange
Dec 28, 2020 08:30AM Ehave, Inc. Announces Repositioning of Mycotopia Therapies to Maximize Shareholder Value
Dec 23, 2020 08:30AM Ehave KetaDASH Subsidiary Announces Intent to Battle Major Depression through Home Delivery of Ketamine
Dec 17, 2020 08:30AM Ehave, Inc. Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
Dec 16, 2020 08:30AM Ehave, Inc. Announces KetaDASH for Ketamine Home Delivery and Purchase of Curedash Assets